些华永道 上海复旦张江生物医药股份有限公司董事会: 普华永道中天会计师事务所(特殊普通合伙)(以下简称"我们"或"普华永道")接受上 海复旦张江生物医药股份有限公司(以下简称"复旦张江")委托,审计了复旦张江 2023 年 12月 31 日的合并及公司资产负债表、2023年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表和财务报表附注(以下合称"2023年度财务报 表")。我们按照中国注册会计师审计准则的规定执行了审计工作,于 2024年 3月 28 日出具了报告号为普华永道中天审字(2023)第 10115 号的无保留意见的审计报告。 按照企业会计准则的规定编制复目张江财务报表是复旦张江管理层的责任。我们的 责任是在实施审计工作的基础上对复旦张江财务报表发表审计意见。 我们阅读了上海证券交易所向复旦张江出具的《关于上海复旦张江生物医药股份有 限公司 2023 年年度报告的信息披露监管问询函》(上证科创公函【2024】0053 号)(以 下简称"2023年年报问询函"),我们以上述我们对 2023 年度财务报表所执行的审计工 作为依据,对复旦张江就 2023年年报问询函中需由年审会计师发 ...

Revenue and Profitability - Revenue for the first quarter was RMB 147,647,109, representing a decrease of 21.94% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 73.29% to RMB 2,347,396[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB -4,515,799, a decline of 292.19%[2] - The company's total operating revenue for Q1 2024 was RMB 147,647,109, a decrease of 22% compared to RMB 189,147,552 in Q1 2023[13] - Operating profit for Q1 2024 was RMB 1,190,039, down from RMB 3,481,590 in Q1 2023, reflecting a significant decline in profitability[13] - The net profit attributable to shareholders for Q1 2024 was RMB 2,347,396, compared to RMB 8,787,158 in the same period last year, indicating a decrease of approximately 73%[13] Research and Development - Research and development expenses totaled RMB 64,173,693, an increase of 17.73% year-on-year[2] - R&D expenses accounted for 43.46% of revenue, up by 14.64 percentage points from the previous year[2] - Research and development expenses for Q1 2024 were RMB 63,616,910, an increase from RMB 54,123,028 in Q1 2023, indicating a focus on innovation despite declining revenues[13] Cash Flow and Liquidity - The net cash flow from operating activities was RMB 43,938,388, a significant improvement from RMB -16,026,020 in the same period last year[5] - In Q1 2024, cash inflow from operating activities was RMB 244,729,122, a 50.0% increase from RMB 162,901,241 in Q1 2023[14] - The net cash flow from operating activities was RMB 43,938,388, compared to a negative RMB 160,260,214 in the same period last year[14] - Cash outflow for purchasing goods and services decreased significantly to RMB 82,458,828 from RMB 228,636,546, marking a 64.0% reduction[14] - The net increase in cash and cash equivalents for the quarter was RMB 37,498,452, compared to a decrease of RMB 401,292,835 in Q1 2023[14] - The ending balance of cash and cash equivalents was RMB 1,233,394,449, up from RMB 888,009,829 in the previous year[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,825,346,356, a decrease of 1.78% from the end of the previous year[2] - Total current assets decreased to RMB 1,833,318,779 from RMB 1,869,424,886, reflecting a decline of about 2%[11] - Total liabilities decreased to RMB 464,492,233 as of March 31, 2024, down from RMB 518,124,139 at the end of 2023, representing a reduction of approximately 10%[12] - Equity attributable to shareholders increased slightly by 0.10% to RMB 2,359,932,124[2] Strategic Changes - The company terminated its cooperation with a promotional service provider, impacting sales revenue of a key product during the reporting period[5] - The company plans to terminate its marketing cooperation with Shanghai Huizheng due to underperformance of its product, Liboduo, which has led to a significant drop in revenue[10] - The company is adjusting its sales strategy for Liboduo by selecting specialized CSO companies for regional marketing and academic promotion to enhance communication efficiency and reduce operational risks[10] - The company aims to leverage various bidding and procurement opportunities to enhance its market presence and adapt its promotional strategies to local conditions[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,860[8] Cash Flow from Investments - Cash inflow from investment activities was RMB 919,724,441, down 13.0% from RMB 1,055,510,659 in Q1 2023[14] - The net cash flow from investment activities was negative RMB 3,807,572, an improvement from negative RMB 235,735,353 year-over-year[14] Financing Activities - Cash outflow related to financing activities decreased to RMB 2,669,076 from RMB 5,251,044, a reduction of 49.2%[14] Accounting Standards - The company has not applied new accounting standards or interpretations for the first quarter of 2024[15]

Financial Performance - The company's revenue for 2023 was RMB 850.733 million, a decrease of 17.5% compared to RMB 1,031.160 million in 2022[11]. - The profit before tax for 2023 was RMB 97.528 million, down from RMB 132.294 million in the previous year, representing a decline of 26.2%[11]. - The total comprehensive income attributable to shareholders for 2023 was RMB 107.970 million, a decrease of 21.1% from RMB 136.847 million in 2022[11]. - Basic and diluted earnings per share attributable to shareholders for 2023 were RMB 0.1051, down from RMB 0.1340 in 2022, a decline of 21.7%[11]. - The company reported a total comprehensive income of RMB 107.793 million for the year, compared to RMB 136.122 million in 2022, indicating a decrease of 21.0%[11]. - Net profit for 2023 was approximately RMB 108,450 thousand, a decline of about 21% from RMB 137,272 thousand in 2022, with a stable net profit margin of 13%[51]. - The profit attributable to shareholders for 2023 was RMB 108,627 thousand, down 21% from RMB 137,997 thousand in 2022[52]. - The group's operating revenue decreased by 17.50% year-on-year due to underperformance in sales of the main product, Ribavirin®[31]. - The sales of Libao Duo® did not meet expectations, leading to a decline in overall revenue and affecting other financial metrics[81]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 2,876.688 million, a slight decrease from RMB 2,976.007 million in 2022[12]. - The company's total liabilities decreased to RMB 518.124 million in 2023 from RMB 722.986 million in 2022, reflecting a reduction of 28.3%[12]. - As of December 31, 2023, the company's long-term equity investment net value was RMB 287,518 thousand, with an investment loss of approximately RMB 23,540 thousand during the reporting period[53]. - As of December 31, 2023, the company had cash and cash equivalents of approximately RMB 1,195,896 thousand, down from RMB 1,289,303 thousand as of December 31, 2022[58]. Research and Development - The company has been focusing on research and development of new technologies to strengthen its competitive position in the biopharmaceutical sector[14]. - The company focuses on innovative research and development in biomedicine, with a strategic emphasis on photodynamic therapy (PDT) and antibody-drug conjugates (ADC) for various diseases[15]. - The company has developed a pipeline of photodynamic drugs targeting conditions such as cervical cancer, breast cancer, and glioma, with ongoing clinical trials for new indications[17]. - The company aims to leverage its competitive advantages in photodynamic technology to strengthen its market position and expand its product offerings[15]. - The company is committed to balancing innovation with industrialization, focusing on both research and market development to ensure sustainable growth[16]. - The company has established multiple technology platforms, including gene engineering and nanotechnology, to support its drug development initiatives[15]. - The company emphasizes the importance of clinical unmet needs in guiding its research and development efforts for photodynamic drugs[17]. - The company is actively pursuing collaborations to accelerate its growth and achieve a stable position in the market[15]. - The company is focused on expanding its ADC drug portfolio and enhancing its R&D capabilities in biopharmaceuticals and small molecules[26]. Clinical Trials and Product Development - The company submitted three clinical trial applications for intraoperative molecular imaging (IMI) technology, aimed at enhancing tumor visualization during surgeries for glioma, bladder cancer, and breast cancer[18]. - The combination of ALA and photodynamic therapy for the treatment of HPV-related cervical precancerous lesions has completed Phase II clinical trials and will soon initiate Phase III trials[19]. - The Phase II clinical trial for ALA photodynamic therapy in treating moderate to severe acne has been completed, with ongoing research into pain-free treatment options[19]. - The application for Phase II clinical trials of ALA granules for intraoperative visualization in breast cancer surgery has been accepted, addressing a significant clinical need in real-time tumor margin assessment[21]. - The application for verification clinical trials of ALA granules for non-muscle invasive bladder cancer surgery has been accepted, aiming to improve tumor detection rates during TURBT procedures[21]. - The application for verification clinical trials of ALA oral solution for visualization in high-grade glioma surgery has been accepted, focusing on enhancing surgical outcomes and patient survival[21]. - The photodynamic drug Revamed (Heimofen injection) is undergoing Phase II clinical trials in the U.S., with expectations for significant clinical benefits upon successful market entry[22]. - The company has completed bioequivalence clinical studies and confirmatory clinical trials for the obeticholic acid project, which targets primary biliary cholangitis (PBC), and will soon apply for production registration[28]. - The company has initiated Phase II clinical studies for the drug FZJ-003 targeting atopic dermatitis and ulcerative colitis, demonstrating its commitment to advancing its pipeline[30]. Market Strategy and Expansion - The company aims to enhance its market expansion strategies and invest in new product development to drive future growth[14]. - The company is actively seeking to expand its presence in international markets to enhance its competitiveness amid ongoing industry reforms and changes in domestic policies[39]. - The company is experiencing a shift in the pharmaceutical industry towards innovation, with a notable increase in investment in R&D for new drugs[39]. - The company is focused on international registration of existing products to enhance treatment value and commercial benefits[31]. - The company plans to terminate the marketing service agreement with Shanghai Huizheng effective December 31, 2023, due to underperformance of the product Liboduo®[43]. Corporate Governance - The company emphasizes a commitment to robust corporate governance to enhance transparency and accountability, thereby protecting shareholder interests[131]. - The audit committee, consisting of two independent non-executive directors and one non-executive director, has reviewed the financial statements and internal controls for the fiscal year 2023[154]. - The independent non-executive directors have confirmed their independence, aligning with regulatory requirements[156]. - The company has established a comprehensive corporate governance code, including rules for various committees and information disclosure systems[178]. - The board consists of two executive directors, two non-executive directors, and three independent non-executive directors, with a total of seven members[180]. Shareholder Information - The proposed final dividend for the year ending December 31, 2023, is RMB 0.07 per share, totaling RMB 72,560,047 (including tax) based on the current issued share capital of 1,036,572,100 shares[119]. - The net profit attributable to ordinary shareholders for 2023 is RMB 108,627,368, resulting in a dividend payout ratio of 66.80%[123]. - The company has maintained a consistent dividend of RMB 0.07 per share over the past three years, with total cash dividends of RMB 72,560,047 in both 2023 and 2022[123]. - Major shareholders include Shanghai Pharmaceuticals with 20.27% of total issued shares and New Venture II with 15.14%[145]. - The top ten shareholders hold a total of 1,037,000,000 shares, representing 102.70% of the total issued shares, indicating significant concentration[146].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 於二零二四年四月一日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 I，同意以日常營 運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 於二零二四年四月二十二日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 II，同意以日常 營運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 浦發銀行結構性存款產品協議 於二零二四年四月二十二日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 II，同意以日 常營運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 上市規則的涵義 就浦發銀行結構性存款產品協議 I 項下產品的認購金額而言，其適用百分比率（定義見上市規則 第 14.07 條）低於 5%，故根據上市規則第 14 章，该交易不構成本公司之須予披露的交 ...

股票代码：688505 公司简称：复旦张江 编号：2024-001 上海复旦张江生物医药股份有限公司 投资者关系活动记录表 （2024 年 4 月 17 日） 上海复旦张江生物医药股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 ...

海通证券股份有限公司关于上海复旦张江生物医药股份有限公司 首次公开发行股票并上市 之保荐总结报告书 | 保荐机构名称： | 海通证券股份有限公司 | | --- | --- | | 保荐机构编号： | Z22531000 | 经中国证券监督管理委员会《关于同意上海复旦张江生物医药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]912 号）批复，上海复旦张江生物医 药股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 12,000 万股，每股面值人民币 0.1 元，每股发行价格人民币 8.95 元，募集资金总 额为人民币 107,400.00 万元，扣除发行费用后，实际募集资金净额为人民币 97,432.39 万元。本次发行证券已于 2020 年 6 月 19 日在上海证券交易所科创板 上市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续督 导保荐机构，持续督导期间为 2020 年 6 月 19 日至 2023 年 12 月 31 日。 2023 年 12 月 31 日，持续督导期已届满，海通证券根据《证券发行上市保荐业 务管理办法》、《上海证券交易 ...

海通证券股份有限公司 关于上海复旦张江生物医药股份有限公司 2023 年度持续督导年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：复旦张江 | | --- | --- | | 保荐代表人姓名：郑乾国、刘勃延 | 被保荐公司代码：688505.SH | 重大事项提示 经中国证券监督管理委员会《关于同意上海复旦张江生物医药股份有限公司 首次公开发行股票注册的批复》（证监许可[2020]912 号）批复，上海复旦张江 生物医药股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发 行股票 12,000 万股，每股面值人民币 0.1 元，每股发行价格人民币 8.95 元，募 集资金总额为人民币 107,400.00 万元，扣除发行费用后，实际募集资金净额为人 民币 97,432.39 万元。本次发行证券已于 2020 年 6 月 19 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"保荐机构"或"海通证券"）担任其持续 督导保荐机构，持续督导期间为 2020 年 6 月 19 日至 2023 年 12 月 31 日。 在 2020 年 6 月 19 日至 2023 年 ...

海通证券股份有限公司 关于上海复旦张江生物医药股份有限公司 经中国证券监督管理委员会《关于同意上海复旦张江生物医药股份有限公 司首次公开发行股票注册的批复》（证监许可[2020]912 号）批复，上海复旦张 江生物医药股份有限公司（以下简称"复旦张江"、"上市公司"、"公司"）首次 公开发行股票 12,000 万股，每股面值人民币 0.1 元，每股发行价格人民币 8.95 元，募集资金总额为人民币 107,400.00 万元，扣除发行费用后，实际募集资金净 额为人民币 97,432.39 万元。本次发行证券已于 2020 年 6 月 19 日在上海证券交 易所上市。海通证券股份有限公司（以下简称"海通证券"、"保荐机构"）担任 其持续督导保荐机构，持续督导期间为 2020 年 6 月 19 日至 2023 年 12 月 31 日。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 有关法律、法规要求，海通证券作为持续督导保荐机构，于 2024 年 3 月 29 日， 对复旦张江进行了现场检查，现将本次现场检查的情况报 ...

股票代码：688505 股票简称：复旦张江 公告编号：临 2024-013 上海复旦张江生物医药股份有限公司 关于参加 2023 年度制药专场集体业绩说明会的公告 本次业绩说明会以视频和线上文字互动形式召开，公司将针对 2023 年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 1 / 3 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 4 月 16 日（周二）16:00 前通过邮件、电话等形式将需要 了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关注的 问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日于上海证券交易所网站（www.sse.com.cn）披露了公司 2023 年年度报告。 为便于广大投资者全面深入地了解公司 2023 年度经营成果、财务状况及发展理 念，公司参与了由上海证券交易所主办的科创板 2023 年度制药专场集体业绩 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購中國銀行結構性存款產品 認購結構性存款產品 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議，同意以 A 股公開發行所得暫時閑置 募集資金向中國銀行認購總金額為人民幣 1.80 億元的結構性存款產品。 上市規則的涵義 根據上市規則第 14.22 條，中國銀行結構性存款產品協議項下的交易需合併計算。在訂立中國銀 行結構性存款產品協議時，就中國銀行結構性存款產品協議項下產品的總認購金額合計而言，一 項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市規則第 14章，该等交易構成本公司之須予披露的交易，須遵守上市規則第14章有關申報及公告之規定， 惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議，同意以 A 股公開發行所得暫時閑置募 集資金向中國銀行認購總金額為人民幣 1.80 億元的結構性存款產品。 - ...